Felix Frueh
Director/Board Member at GENINCODE PLC
Net worth: 9 078 $ as of 2024-04-29
Profile
Felix Wilhelm Frueh is the founder of Profound Ventures LLC, Selva Therapeutics, Inc, and currently serves as an Independent Non-Executive Director at GENinCode Plc.
He previously served as the Chief Executive Officer of Intellos Health LLC, Director of Transgenomic, Inc., Non-Executive Director of Ariana Pharmaceuticals SA, Assistant Director of Protogene Laboratories, Inc., Independent Non-Executive Director of Enterome SA, President of King Pharmaceuticals Research & Development, Inc., Assistant Professor at Georgetown University, Entrepreneur-in-Residence at Third Rock Ventures LLC, Chief Scientific Officer of Human Longevity, Inc., and Partner at Opus Three LLC.
He holds a doctorate degree from the University of Basel.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
GENINCODE PLC
0.06% | 2024-04-25 | 100,000 ( 0.06% ) | 9 078 $ | 2024-04-29 |
Felix Frueh active positions
Companies | Position | Start |
---|---|---|
GENINCODE PLC | Director/Board Member | 2022-04-05 |
Profound Ventures LLC
Profound Ventures LLC Investment ManagersFinance Profound Ventures LLC solves profound societal problems. It engaged in creating, seed funding, and growing new business ventures and non-profit organizations to solve. The company was founded by Felix Frueh and Brian Meshkin and is headquartered in Newport Beach, CA. | Founder | - |
Former positions of Felix Frueh
Companies | Position | End |
---|---|---|
Georgetown University | Corporate Officer/Principal | 2000-12-30 |
Protogene Laboratories, Inc. | Corporate Officer/Principal | 2000-12-30 |
King Pharmaceuticals Research & Development, Inc. | President | - |
Opus Three LLC | Corporate Officer/Principal | - |
Human Longevity, Inc.
Human Longevity, Inc. BiotechnologyHealth Technology Human Longevity, Inc. provides precision health analytics to individuals through the Health Nucleus. The Health Nucleus is an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. The firm offers database of sequenced genomes and phenotypic data. The company was founded by J. Craig Venter, Robert Joseph Hariri Gordon, and Peter H. Diamandis in 2013 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Training of Felix Frueh
University of Basel | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
GENINCODE PLC | Technology Services |
Private companies | 11 |
---|---|
King Pharmaceuticals Research & Development, Inc. | Health Technology |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Health Technology |
Ariana Pharmaceuticals SA
Ariana Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Ariana Pharmaceuticals SA provides pharmaceutical, clinical and data technology. It offers analytics for multi-paramedic data in identifying patient responders to reduce clinical and drug development risk. The firm also develops biomarker signatures to develop processes in anawlyzing multi-paramedic data. The company was founded by Mohammad Afshar in 2003 and is headquartered in Paris, France. | Health Technology |
Protogene Laboratories, Inc. | |
Enterome SA
Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Health Technology |
Human Longevity, Inc.
Human Longevity, Inc. BiotechnologyHealth Technology Human Longevity, Inc. provides precision health analytics to individuals through the Health Nucleus. The Health Nucleus is an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. The firm offers database of sequenced genomes and phenotypic data. The company was founded by J. Craig Venter, Robert Joseph Hariri Gordon, and Peter H. Diamandis in 2013 and is headquartered in San Diego, CA. | Health Technology |
Profound Ventures LLC
Profound Ventures LLC Investment ManagersFinance Profound Ventures LLC solves profound societal problems. It engaged in creating, seed funding, and growing new business ventures and non-profit organizations to solve. The company was founded by Felix Frueh and Brian Meshkin and is headquartered in Newport Beach, CA. | Finance |
Selva Therapeutics, Inc.
Selva Therapeutics, Inc. BiotechnologyHealth Technology Selva Therapeutics, Inc. is a privately held biotechnology company that is dedicated to developing therapeutics for infectious diseases. The company is based in Del Mar, CA. The company's main focus is on rapidly developing SLV213 for COVID-19, which has the potential to fight multiple life-threatening infectious diseases. Selva Therapeutics was founded by Thomas E. Daley and Felix Wilhelm Frueh, and Thomas E. Daley has been the CEO since incorporation. | Health Technology |
Intellos Health LLC | |
Opus Three LLC | |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
- Stock Market
- Insiders
- Felix Frueh